DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC7675 | BX-471（ZK 811752） Featured | BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. |
|
| DC10357 | Cenerimod | Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM. |
|
| DC8936 | Fingolimod | Fingolimod(FTY720 free base) is a S1P antagonist with IC50 of 0.033 nM. |
|
| DC3154 | Fingolimod HCl（FTY-720） Featured | FTY720 (Fingolimod, Gilenya) is a S1P antagonist with IC50 of 0.033 nM. |
|
| DC2071 | ABR-215062 (Laquinimod) Featured | Laquinimod (ABR-215062) is a potent immunomodulator. |
|
| DC3167 | MK0812 | MK-0812 is chemokine receptor CCR-2 antagonist |
|
| DC8281 | Ozanimod (RPC1063) Featured | Ozanimod (RPC1063) is a selective S1P1R modulator |
|
| DC8741 | Plerixafor octahydrochloride Featured | Plerixafor octahydrochloride(AMD3100 8HCL) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
|
| DC9742 | Ponesimod Featured | Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM. |
|
| DC9490 | Zaurategrast | Zaurategrast(CDP-323) is an oral α4-integrin inhibitor. |
|
| DC12355 | Ceralifimod (ONO-4641) | Ceralifimod is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively. |
|
| DC7694 | BAF312 (Siponimod) Featured | BAF312 is a potent and selective agonist of S1P with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively |
|
